Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?
The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 18×
“However, although AMPK activation is one mechanism by which mTOR could be suppressed by stress, several other mechanisms have been proposed to explain how mTOR is regulated during shorter time periods, when ATP levels may still be in the normal range.”
BackgroundInfluentialUpstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Self-citationTSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Self-citationKim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
A mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
Cited by
p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling
Budanov, A. V., & Karin, M. (2008) · Cell · doi:10.1016/j.cell.2008.06.028 · Cited by 1,326
Life and death partners: apoptosis, autophagy and the cross-talk between them
Eisenberg-Lerner, A., Bialik, S., Simon, H.-U., & Kimchi, A. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2009.33 · Cited by 1,183
Wu, Y.-T., Tan, H.-L., Shui, G., Bauvy, C., Huang, Q., Wenk, M. R., Ong, C.-N., Codogno, P., & Shen, H.-M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.080796 · Cited by 1,127
Meloche, S., & Pouysségur, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210414 · Cited by 1,091
“…2004; Hay and Sonenberg, 2004; Wullschleger et al., 2006 for reviews). mTOR activity is negatively regulated by the tuberous sclerosis complex 1 (TSC1)/TSC2 heterodimer, which acts as a GTPase activating protein (GAP) for the small GTPase Rheb (Manning and Cantley, 2003; Corradetti and Guan, 2006).”
BackgroundHeras-Sandoval, D., Pérez-Rojas, J. M., Hernández-Damián, J., & Pedraza-Chaverri, J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.08.019 · Cited by 1,091
Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium
Høyer-Hansen, M., & Jäättelä, M. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402200 · Cited by 766
The regulation and function of Class III PI3Ks: novel roles for Vps34
Backer, J. M. (2008) · Biochemical Journal · doi:10.1042/bj20071427 · Cited by 659
Signalling to translation: How signal transduction pathways control the protein synthetic machinery
Proud, C. G. (2007) · Biochemical Journal · doi:10.1042/bj20070024 · Cited by 520
Adipose-Specific Knockout of raptor Results in Lean Mice with Enhanced Mitochondrial Respiration
Polak, P., Cybulski, N., Feige, J. N., Auwerx, J., Rüegg, M. A., & Hall, M. N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.003 · Cited by 480
O'Donnell, A., Faivre, S., Burris, H. A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0988 · Cited by 479
Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1
Dibble, C. C., Asara, J. M., & Manning, B. D. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00735-09 · Cited by 423
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297
“In recent years, the complexity of the PI3K/Akt/mTOR pathway has become increasingly apparent, particularly in relation to its potential as a therapeutic target in cancer.(43,44) Recent data suggest the presence of a negative feedback loop, whereby increased activation of mTOR leads to a physiologic brake on further s…”
BackgroundPRAS40 and PRR5-Like Protein Are New mTOR Interactors that Regulate Apoptosis
Thedieck, K., Polak, P., Kim, M. L., Molle, K. D., Cohen, A., Jenö, P., Arrieumerlou, C., & Hall, M. N. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001217 · Cited by 296
Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities
Plati, J., Bucur, O., & Khosravi‐Far, R. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21707 · Cited by 293
Foster, D. A., Yellen, P., Xu, L., & Saqcena, M. (2010) · Genes & Cancer · doi:10.1177/1947601910392989 · Cited by 275
Zhao, Y., Xiong, X., & Sun, Y. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.029 · Cited by 272
Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells
Schmitz, F., Heit, A., Dreher, S., Eisenächer, K., Mages, J., Haas, T., Krug, A., Janssen, K., Kirschning, C. J., & Wagner, H. (2008) · European Journal of Immunology · doi:10.1002/eji.200838761 · Cited by 212
Sato, T., Nakashima, A., Guo, L., & Tamanoi, F. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809207200 · Cited by 196
Averous, J., Fonseca, B. D., & Proud, C. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210715 · Cited by 194
“…roles are those mediated by mTORC1, which is sensitive to the immunosuppressant drug rapamycin. mTORC1 signaling is activated by signaling via phosphatidylinositide 3-kinase and protein kinase B (PKB, also termed Akt) and by the Ras/Raf/ERK pathway (Corradetti and Guan, 2006).”
Mechanotransduction and the regulation of mTORC1 signaling in skeletal muscle
Hornberger, T. A. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.05.007 · Cited by 170
“Signaling by the mTORC2 complex is not directly inhibited by rapamycin, and thus, it seems unlikely that signaling by the mTORC2 complex contributes to the growth-regulatory effects that have been attributed to the rapamycinsensitive pathway (Corradetti and Guan, 2006, Jacinto et al., 2004).”
BackgroundTipping the metabolic scales towards increased longevity in mammals
Riera, C. E., & Dillin, A. (2015) · Nature Cell Biology · doi:10.1038/ncb3107 · Cited by 153
Feng, X., Huang, D., Lu, X., Feng, G., Xing, J., Lu, J., Xu, K., Xia, W., Meng, Y., Tao, T., et al. (2014) · Development, Growth & Differentiation · doi:10.1111/dgd.12179 · Cited by 101
Mammalian Target of Rapamycin and S6 Kinase 1 Positively Regulate 6-thioguanine-Induced Autophagy
Zeng, X., & Kinsella, T. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6163 · Cited by 94
Maddodi, N., Huang, W., Havighurst, T., Kim, K., Jack Longley, B., & Setaluri, V. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.26 · Cited by 80
“There are two distinct mTOR complexes, mTORC1 and mTORC2, that consist of distinct mTORbinding proteins and also have different substrate specificities (Corradetti and Guan, 2006).”
RalA Functions as an Indispensable Signal Mediator for the Nutrient-sensing System
Maehama, T., Tanaka, M., Nishina, H., Murakami, M., Kanaho, Y., & Hanada, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805822200 · Cited by 80
Chen, X., Jiang, C., Sun, R., Yang, D., & Liu, Q. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.010 · Cited by 66
Proteinuria causes dysfunctional autophagy in the proximal tubule
Nolin, A. C., Mulhern, R. M., Panchenko, M. V., Pisarek-Horowitz, A., Wang, Z., Shirihai, O., Borkan, S. C., & Havasi, A. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00125.2016 · Cited by 58
Chauvin, C., Salhi, S., & Jean-Jean, O. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00035-07 · Cited by 58
“In contrast, mTORC2, which is rapamycin insensitive, has been shown to control actin cytoskeleton dynamics ( 8 ).”
Background(2010) · PubMed Central
Metadata
- Authors
- Corradetti, M. N., & Guan, K.-L.
- Venue
- Oncogene
- Published
- 2006-10-16
- Volume
- 25
- Issue
- 48
- Pages
- 6347-6360
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2010538519
- Cited by
- 386
- References
- 142
- FWCI
- 12.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.